Abstract

Preclinical drug discovery datasets continue to evolve in complexity and throughput as advancing drug discovery technologies continues to yield complex and diverse omics-based datasets. The automation solutions provided by Beckman Coulter Life Sciences continue to generate value for our customers by facilitating the automation of numerous assays and workflows in developing areas such as chemical transcriptomics, ‘synbio-pharma’ workflows, and more physiologically relevant screens. Our platforms facilitate cost reductions through miniaturization while simultaneously maintaining high data quality by combining instruments designed for precision with easy-to-use software packages. In this presentation, we will explore our solutions and areas in which our customers are able to deploy scalable automation solutions to generate actionable data.